Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington.

The Cure survey said China leads in clinical development and supply chain, and rated US funding cuts a bigger threat than China competition.

Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington.